Instil Bio, Inc. (TIL)

Market Cap	69.92M
Revenue (ttm)	n/a
Net Income (ttm)	-156.09M
Shares Out	6.50M
EPS (ttm)	-24.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,073
Open	10.78
Previous Close	10.71
Day's Range	10.60 - 10.78
52-Week Range	6.08 - 14.00
Beta	1.25
Analysts	Buy
Price Target	27.67 (+157.4%)
Earnings Date	May 9, 2024

About TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 19, 2021
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: TIL

Analyst Forecast

According to 3 analysts, the average rating for TIL stock is "Buy." The 12-month stock price forecast is $27.67, which is an increase of 157.40% from the latest price.

Price Target

$27.67

(157.40% upside)

Analyst Consensus: Buy